NovaMedica and Ferring Pharmaceuticals bring Innovative Gastroenterological Products from Switzerland to Russia
Wednesday, June 03, 2015
NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices.
Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market.
“The agreement with Ferring opens up broad prospects for the development of products for the treatment of gastroenterological diseases, which are one of the most widely spread and significant medical problems in Russia. Through this collaboration, we will be able to offer Russian specialists and patients new solutions for treatment using effective medicines,” noted Fabrice Egros, the COO of NovaMedica.
“We are glad to collaborate with NovaMedica and believe that this company is the right choice because of its long-term strategy targeted at bringing innovative gastroenterological products to Russian patients,” said Kirill Litovchenko, General Manager of Ferring Russia.
finance.yahoo.com
